ÍþÁ®Ï£¶û¹ÙÍøµØÖ·

ÈÈÃÅËÑË÷
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾ Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
ÐÂÎÅ×ÊѶ
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
2026-03-04
ÍþÁ®Ï£¶û¹ÙÍøµØÖ· Immutailin? PVDFתӡĤÐÂÆ·ÉÏÊÐ
ÔÚÂѰ×ÖÊÓëºËËá¼ì²âÆÊÎöÓ¦ÓÃÖУ¬NC תӡĤ£¨ÏõËáÏËÎ¬ËØÄ¤£©ÓëPVDF ×ªÓ¡Ä¤£¨¾ÛÆ«¶þ·úÒÒϩĤ£©ÊÇÁ½Ïî½¹µãµÄ¹ÌÏàÖ§³Ö½éÖÊ¡£ËüÃÇÒÀ¸½¸÷×ÔÆæÒìµÄÐÔÄÜÓÅÊÆ£¬ÆÕ±éÓ¦ÓÃÓÚ¿ÆÑÐ̽Ë÷ÓëҽѧÕï¶ÏÁìÓò£¬Îª²î±ðµÄʵÑéÄ¿µÄ¡­
Éó²éÏêÇé
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
242026.02
¿¥ÆôгÌ£¬ÂíÁ¦È«¿ª£¡ ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï½ñÈÕ¿ª¹¤À²£¡
·Ü½øÕýÆäʱ£¬¿ª¹¤Æôг̣¡ÏÄÀúÕýÔ³õ°ËÉÏÎ磬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïдº¿ª¹¤ÒÇʽÔÚ¸÷¸öÔ°ÇøÍ¬²½¾ÙÐС£È«ÌåÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÈË´ø×ÅдºµÄÉúÆøÖØ·µ¸Úλ£¬Ñ¸ËÙ´Ó¡°¼ÙÆÚģʽ¡±Çл»ÖÁ¡°ÊÂÇéģʽ¡±£¬ÒÔ»ðÈÈ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
112026.02
¿Í»§µÄ ¡°ÕÙ»½¡± £¬ÎÒÃÇÕâÑù»ØÓ¦
2025 ÍþÁ®Ï£¶û¹ÙÍøµØÖ·Äê¶È·þÎñ±¨¸æ ¡ª¡ªÒÔ·þÎñÖ®¹â£¬ÕÕÁÁ¿Æ¼¼Ö®Â·¡ª¡ª¡°ÒÔ¿Í»§ÎªÖÐÐÄ¡±ÊÇÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïµÄ·þÎñ×ÚÖ¼ÎÒÃÇÓÅ»¯Á÷³Ì¡¢Á¢Òì¼Æ»®ÓÃÐж¯Ú¹ÊÍ·þÎñ¼ÛÖµÓÃרҵÓëζÈÓ®µÃ¿Í»§ÐÅÈÎÕâ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
112026.02
?ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸ºÑ¹¸ôÀëÆ÷ÊÖÒÕÔڸ߻îÐÔÖÊÁÏÒ©Éú²úÖеÄÓ¦ÓÃ
Ò»¡¢¹æÔò¶Ô¶¾ÐÔÒ©Æ·Éú²úµÄÏà¹Ø»®¶¨¡ñ WHO TRS-957 ANNEX 3 WHO good manufacturing practices for pharmaceutical products containing hazardous substance¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
302026.01
ÍòÂíÍØÐ ¹²Ô¾É½º£ | ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÔ²ÂúÂäÄ»£¡
1ÔÂ28ÈÕ£¬¡°ÍòÂíÍØÐ ¹²Ô¾É½º£¡±¡ª¡ªÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÊ¢´ó¾ÙÐС£ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¶­Ê³¤Ò¶´óÁÖÏÈÉú£¬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸±×ܲÃÉòÖ¾ÁÖÏÈ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
232026.01
ϲ±¨£¡ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÆÊÎö»ñÅú¡°Õã½­Ê¡ÆóÒµÑо¿Ôº¡±£¬Ñз¢ÊµÁ¦»ñÊ¡¼¶È¨ÍþÈÏÖ¤£¡
¿ËÈÕ£¬Õã½­ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÆÊÎöÒÇÆ÷ÓÐÏÞ¹«Ë¾ÒÀ¸½ÉîÖ¿µÄÊÖÒÕ»ýµí¡¢Ò»Á¬µÄÁ¢ÒìÄÜÁ¦ÓëÐÐÒµÁìÏȵÄÑз¢Ë®Æ½£¬ÀֳɻñÅú¡°Õã½­Ê¡ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÖÇÄÜ»¯ÆÊÎöÒÇÆ÷ÆóÒµÑо¿Ôº¡±£¨Õ㾭ПßÐÂ˽º¯¡²2025¡³165ºÅ¡­
ÍøÕ¾µØÍ¼